Last updated: February 19, 2026
Who Are the Main Suppliers of Clopidogrel (Plavix)?
Clopidogrel bisulfate, marketed as Plavix, is a widely used antiplatelet medication. Its manufacturing involves several key suppliers, including active pharmaceutical ingredient (API) producers and finished drug manufacturers.
What Are the Leading API Suppliers for Clopidogrel?
Several companies supply the active ingredient (API) used in Plavix. The primary API producers include:
- Korea Yakult Pharmaceutical Industry Co. Ltd.
- Jiangsu Hengrui Medicine Co. Ltd.
- Taj Pharmaceuticals Ltd.
- Mylan N.V. (partnered with the original manufacturer Sanofi)
These companies have established manufacturing processes compliant with the standards set by regulatory authorities like the FDA, EMA, and the Chinese NMPA.
Who Manufactures the Finished Product of Plavix?
Sanofi, the original developer, licensed the drug to Bristol-Myers Squibb. Currently, the marketed version is primarily produced by:
Manufacturers in India, China, and other countries produce generics under local and international licensing agreements.
How Is the Supply Chain Structured?
The supply chain involves:
- API Production: Raw material synthesis and API manufacturing, often in China, India, South Korea, or Europe.
- Formulation and Packaging: Conversion of API into finished tablets, often in regional manufacturing plants.
- Distribution: Global distribution via wholesalers and logistics providers, with approvals in multiple markets.
Key aspects are:
- API suppliers typically export to contract manufacturers for formulation.
- Regulatory approvals influence the sourcing and market access.
- Regional manufacturing licenses determine availability in different countries.
Market Dynamics and Regulatory Impact
Supply is affected by:
- Regulatory approvals and changes. For example, the FDA's requirement for stringent testing can affect API sourcing.
- Patent status. Plavix's patents expired in many territories, increasing generic competition.
- Manufacturing capacity and quality standards. Increased demand for antiplatelet therapies drives investment in API production facilities.
Summary Table of Key Suppliers
| Supplier |
Region |
API Production |
Market Presence |
Notes |
| Korea Yakult |
South Korea |
Yes |
Global |
Focused on high-quality API, licensed for export |
| Jiangsu Hengrui |
China |
Yes |
Asia, emerging markets |
Leading Chinese API manufacturer |
| Mylan |
International |
Yes |
Global |
Large-scale generic producer, licensing agreements |
| Teva |
Israel |
Yes |
Global |
Significant market share in generics |
| Sanofi |
France |
No (licensed to others) |
Original manufacturer |
Patent holder in early markets |
Key Takeaways
- Multiple API producers supply the raw material for Plavix, with South Korea, China, and India playing dominant roles.
- Sanofi remains the primary manufacturer of the branded product, with numerous generics available globally.
- Supply chain complexity involves API manufacturing, formulation, and distribution, with regional licensing impacting availability.
- Regulatory approval processes significantly influence manufacturing and supply stability.
- Market shifts post-patent expiry increased generic competition, expanding supplier options and decreasing prices.
Frequently Asked Questions
1. Who manufactures the active ingredient in Plavix?
Korea Yakult, Jiangsu Hengrui, and other Chinese and Korean firms supply the API; some European companies also produce it.
2. Are there multiple manufacturers of generic Plavix?
Yes. Several generic producers, such as Mylan, Teva, and Lupin, manufacture clopidogrel.
3. Where is the supply of Plavix concentrated?
The supply chain primarily centers in China, India, and South Korea, with regional manufacturing and distribution hubs.
4. How does patent expiration affect suppliers?
Patent expiration in many regions allowed numerous generics to enter the market, increasing supplier diversity and reducing prices.
5. What regulatory factors influence supplier stability?
Regulatory approvals, quality standards, and licensing agreements shape supplier participation and supply continuity.
References
- U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
- European Medicines Agency. (2021). Summary of Product Characteristics: Plavix.
- World Health Organization. (2020). WHO Model List of Essential Medicines.
- MarketWatch. (2023). Global Clopidogrel Market Trends.
- FDA Drug Recalls Database. (2022). Regulatory actions affecting API and finished drug manufacturing.
